{"id":"ketoprofen-and-omeprazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL571","moleculeType":"Small molecule","molecularWeight":"254.29"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a fixed-dose combination pairing an NSAID (ketoprofen) with a proton pump inhibitor (omeprazole). Ketoprofen blocks cyclooxygenase enzymes to reduce prostaglandin-mediated inflammation, pain, and fever. Omeprazole reduces gastric acid secretion by inhibiting the H+/K+-ATPase pump, thereby mitigating the gastrointestinal toxicity risk inherent to chronic NSAID use.","oneSentence":"Ketoprofen inhibits prostaglandin synthesis via COX inhibition to reduce inflammation and pain, while omeprazole suppresses gastric acid production to protect against NSAID-induced ulcers.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:51:02.341Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis with gastric protection"},{"name":"Osteoarthritis with gastric protection"},{"name":"Chronic pain conditions requiring NSAID therapy with reduced GI risk"}]},"trialDetails":[{"nctId":"NCT05925140","phase":"PHASE1","title":"LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Lebanese University","startDate":"2020-03-28","conditions":"COVID-19, Hospitalized COVID-19 Patients","enrollment":1000},{"nctId":"NCT02730026","phase":"PHASE4","title":"Comparison of the Clinical Efficacy of Ketoprofen, Associated or Not With Omeprazole in Lower Third Molar Removal","status":"COMPLETED","sponsor":"Luis Fernando Simoneti","startDate":"2015-06","conditions":"Pain, Other Surgical Procedures","enrollment":50},{"nctId":"NCT00971581","phase":"PHASE3","title":"Safety, Tolerability and Efficacy Study With a Fixed-Dose Combination (FDC) Ketoprofen Plus Omeprazole","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-08","conditions":"Pain","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lower third molar surgery with Ketoprofen and Omeprazole"],"phase":"marketed","status":"active","brandName":"Ketoprofen and Omeprazole","genericName":"Ketoprofen and Omeprazole","companyName":"Luis Fernando Simoneti","companyId":"luis-fernando-simoneti","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ketoprofen inhibits prostaglandin synthesis via COX inhibition to reduce inflammation and pain, while omeprazole suppresses gastric acid production to protect against NSAID-induced ulcers. Used for Rheumatoid arthritis with gastric protection, Osteoarthritis with gastric protection, Chronic pain conditions requiring NSAID therapy with reduced GI risk.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}